Efficacy of the non-adenosine analogue A1 adenosine receptor agonist (BR-4935) on cardiovascular function after cardiopulmonary bypass

G. Veres, T. Radovits, G. Otila, K. Hirschberg, H. Haider, N. Krieger, A. Knoll, E. Weigang, Z. Szabolcs, M. Karck, G. Szabó

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: We tested the hypothesis that pharmacological preconditioning with a newly developed, potent non-adenosine analogue A1AdoR agonist (BR-4935) improves biventricular cardiac and endothelial function after cardiopulmonary bypass. Methods: Twelve anesthetized dogs underwent cardiopulmonary bypass. Dogs were divided into two groups: group 1 (n=6) received saline vehicle, group 2 (n=6) received BR-4935 before cardiopulmonary bypass. Biventricular hemodynamic variables were measured using a combined pressure-volume conductance catheter. Coronary blood flow, ATP content, malondialdehyde and myeloperoxidase levels and vasodilatative responses to acetylcholine and sodium nitroprusside were also determined. Results: Administration of the A1AdoR agonist led to a significantly better recovery of left and right ventricular systolic function after 60 minutes of reperfusion. Although the vasodilatative response to sodium nitroprusside was similar in both groups, acetylcholine resulted in a significantly greater increase in coronary blood flow in the BR-4935 group. In addition, the ATP content was significantly higher in the same group. Furthermore, malondialdehyde and myeloperoxidase levels significantly decreased in the A1AdoR group. Conclusion: Pharmacological preconditioning with a new, potent non-adenosine analogue A1AdoR agonist improves biventricular function recovery and endothelial function after hypothermic cardiac arrest.

Original languageEnglish
Pages (from-to)86-92
Number of pages7
JournalThoracic and Cardiovascular Surgeon
Volume58
Issue number2
DOIs
Publication statusPublished - 2010

Fingerprint

Adenosine A1 Receptor Agonists
Cardiopulmonary Bypass
Nitroprusside
Malondialdehyde
Peroxidase
Acetylcholine
Adenosine Triphosphate
Pharmacology
Dogs
Right Ventricular Function
Recovery of Function
Heart Arrest
Reperfusion
Catheters
Hemodynamics
Pressure
BR-4935

Keywords

  • Cardiovascular surgery
  • Coronary bypass surgery
  • Myocardial protection

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Efficacy of the non-adenosine analogue A1 adenosine receptor agonist (BR-4935) on cardiovascular function after cardiopulmonary bypass. / Veres, G.; Radovits, T.; Otila, G.; Hirschberg, K.; Haider, H.; Krieger, N.; Knoll, A.; Weigang, E.; Szabolcs, Z.; Karck, M.; Szabó, G.

In: Thoracic and Cardiovascular Surgeon, Vol. 58, No. 2, 2010, p. 86-92.

Research output: Contribution to journalArticle

Veres, G. ; Radovits, T. ; Otila, G. ; Hirschberg, K. ; Haider, H. ; Krieger, N. ; Knoll, A. ; Weigang, E. ; Szabolcs, Z. ; Karck, M. ; Szabó, G. / Efficacy of the non-adenosine analogue A1 adenosine receptor agonist (BR-4935) on cardiovascular function after cardiopulmonary bypass. In: Thoracic and Cardiovascular Surgeon. 2010 ; Vol. 58, No. 2. pp. 86-92.
@article{e3ee7f57041b479ea8d88040dfc47709,
title = "Efficacy of the non-adenosine analogue A1 adenosine receptor agonist (BR-4935) on cardiovascular function after cardiopulmonary bypass",
abstract = "Background: We tested the hypothesis that pharmacological preconditioning with a newly developed, potent non-adenosine analogue A1AdoR agonist (BR-4935) improves biventricular cardiac and endothelial function after cardiopulmonary bypass. Methods: Twelve anesthetized dogs underwent cardiopulmonary bypass. Dogs were divided into two groups: group 1 (n=6) received saline vehicle, group 2 (n=6) received BR-4935 before cardiopulmonary bypass. Biventricular hemodynamic variables were measured using a combined pressure-volume conductance catheter. Coronary blood flow, ATP content, malondialdehyde and myeloperoxidase levels and vasodilatative responses to acetylcholine and sodium nitroprusside were also determined. Results: Administration of the A1AdoR agonist led to a significantly better recovery of left and right ventricular systolic function after 60 minutes of reperfusion. Although the vasodilatative response to sodium nitroprusside was similar in both groups, acetylcholine resulted in a significantly greater increase in coronary blood flow in the BR-4935 group. In addition, the ATP content was significantly higher in the same group. Furthermore, malondialdehyde and myeloperoxidase levels significantly decreased in the A1AdoR group. Conclusion: Pharmacological preconditioning with a new, potent non-adenosine analogue A1AdoR agonist improves biventricular function recovery and endothelial function after hypothermic cardiac arrest.",
keywords = "Cardiovascular surgery, Coronary bypass surgery, Myocardial protection",
author = "G. Veres and T. Radovits and G. Otila and K. Hirschberg and H. Haider and N. Krieger and A. Knoll and E. Weigang and Z. Szabolcs and M. Karck and G. Szab{\'o}",
year = "2010",
doi = "10.1055/s-0029-1186271",
language = "English",
volume = "58",
pages = "86--92",
journal = "Thoracic and Cardiovascular Surgeon",
issn = "0171-6425",
publisher = "Georg Thieme Verlag",
number = "2",

}

TY - JOUR

T1 - Efficacy of the non-adenosine analogue A1 adenosine receptor agonist (BR-4935) on cardiovascular function after cardiopulmonary bypass

AU - Veres, G.

AU - Radovits, T.

AU - Otila, G.

AU - Hirschberg, K.

AU - Haider, H.

AU - Krieger, N.

AU - Knoll, A.

AU - Weigang, E.

AU - Szabolcs, Z.

AU - Karck, M.

AU - Szabó, G.

PY - 2010

Y1 - 2010

N2 - Background: We tested the hypothesis that pharmacological preconditioning with a newly developed, potent non-adenosine analogue A1AdoR agonist (BR-4935) improves biventricular cardiac and endothelial function after cardiopulmonary bypass. Methods: Twelve anesthetized dogs underwent cardiopulmonary bypass. Dogs were divided into two groups: group 1 (n=6) received saline vehicle, group 2 (n=6) received BR-4935 before cardiopulmonary bypass. Biventricular hemodynamic variables were measured using a combined pressure-volume conductance catheter. Coronary blood flow, ATP content, malondialdehyde and myeloperoxidase levels and vasodilatative responses to acetylcholine and sodium nitroprusside were also determined. Results: Administration of the A1AdoR agonist led to a significantly better recovery of left and right ventricular systolic function after 60 minutes of reperfusion. Although the vasodilatative response to sodium nitroprusside was similar in both groups, acetylcholine resulted in a significantly greater increase in coronary blood flow in the BR-4935 group. In addition, the ATP content was significantly higher in the same group. Furthermore, malondialdehyde and myeloperoxidase levels significantly decreased in the A1AdoR group. Conclusion: Pharmacological preconditioning with a new, potent non-adenosine analogue A1AdoR agonist improves biventricular function recovery and endothelial function after hypothermic cardiac arrest.

AB - Background: We tested the hypothesis that pharmacological preconditioning with a newly developed, potent non-adenosine analogue A1AdoR agonist (BR-4935) improves biventricular cardiac and endothelial function after cardiopulmonary bypass. Methods: Twelve anesthetized dogs underwent cardiopulmonary bypass. Dogs were divided into two groups: group 1 (n=6) received saline vehicle, group 2 (n=6) received BR-4935 before cardiopulmonary bypass. Biventricular hemodynamic variables were measured using a combined pressure-volume conductance catheter. Coronary blood flow, ATP content, malondialdehyde and myeloperoxidase levels and vasodilatative responses to acetylcholine and sodium nitroprusside were also determined. Results: Administration of the A1AdoR agonist led to a significantly better recovery of left and right ventricular systolic function after 60 minutes of reperfusion. Although the vasodilatative response to sodium nitroprusside was similar in both groups, acetylcholine resulted in a significantly greater increase in coronary blood flow in the BR-4935 group. In addition, the ATP content was significantly higher in the same group. Furthermore, malondialdehyde and myeloperoxidase levels significantly decreased in the A1AdoR group. Conclusion: Pharmacological preconditioning with a new, potent non-adenosine analogue A1AdoR agonist improves biventricular function recovery and endothelial function after hypothermic cardiac arrest.

KW - Cardiovascular surgery

KW - Coronary bypass surgery

KW - Myocardial protection

UR - http://www.scopus.com/inward/record.url?scp=77949992047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949992047&partnerID=8YFLogxK

U2 - 10.1055/s-0029-1186271

DO - 10.1055/s-0029-1186271

M3 - Article

C2 - 20333570

AN - SCOPUS:77949992047

VL - 58

SP - 86

EP - 92

JO - Thoracic and Cardiovascular Surgeon

JF - Thoracic and Cardiovascular Surgeon

SN - 0171-6425

IS - 2

ER -